Cargando…
SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Masson SAS.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836403/ https://www.ncbi.nlm.nih.gov/pubmed/32562762 http://dx.doi.org/10.1016/j.diabet.2020.06.003 |
| _version_ | 1783642741854437376 |
|---|---|
| author | Scheen, A.J. |
| author_facet | Scheen, A.J. |
| author_sort | Scheen, A.J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7836403 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Masson SAS. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78364032021-01-26 SGLT2 inhibition during the COVID-19 epidemic: Friend or foe? Scheen, A.J. Diabetes Metab Commentary Elsevier Masson SAS. 2020-10 2020-06-17 /pmc/articles/PMC7836403/ /pubmed/32562762 http://dx.doi.org/10.1016/j.diabet.2020.06.003 Text en © 2020 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Commentary Scheen, A.J. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe? |
| title | SGLT2 inhibition during the COVID-19 epidemic: Friend or foe? |
| title_full | SGLT2 inhibition during the COVID-19 epidemic: Friend or foe? |
| title_fullStr | SGLT2 inhibition during the COVID-19 epidemic: Friend or foe? |
| title_full_unstemmed | SGLT2 inhibition during the COVID-19 epidemic: Friend or foe? |
| title_short | SGLT2 inhibition during the COVID-19 epidemic: Friend or foe? |
| title_sort | sglt2 inhibition during the covid-19 epidemic: friend or foe? |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836403/ https://www.ncbi.nlm.nih.gov/pubmed/32562762 http://dx.doi.org/10.1016/j.diabet.2020.06.003 |
| work_keys_str_mv | AT scheenaj sglt2inhibitionduringthecovid19epidemicfriendorfoe |